FOMX - Foamix Pharmaceuticals Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.69
-0.11 (-1.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.80
Open5.82
Bid0.00 x 3000
Ask7.05 x 800
Day's Range5.66 - 5.90
52 Week Range4.34 - 7.45
Volume50,731
Avg. Volume91,065
Market Cap230.467M
Beta2.53
PE Ratio (TTM)N/A
EPS (TTM)-2.06
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.50
Trade prices are not sourced from all markets
  • GlobeNewswire20 days ago

    CORRECTING and REPLACING -- Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103

    In a release issued under the same headline earlier today by Foamix (FOMX), please note that in the second paragraph of the release, the top-line data announcement should be in the third quarter, not early in the fourth, as previously stated. REHOVOT, Israel, and BRIDGEWATER, N.J., June 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it has completed patient enrollment and has dosed the last patient in its two Phase 3 clinical studies (FX2016-11 and FX2016-12) evaluating the safety and efficacy of FMX103, topical minocycline foam 1.5%, for the treatment of rosacea.  The two Phase 3 pivotal studies are being run simultaneously, and the Company currently anticipates reporting top-line results early in the fourth quarter of this year.

  • GlobeNewswirelast month

    Foamix Pharmaceuticals to Participate in the Cantor Dermatology & Aesthetics Summit

    REHOVOT, Israel and BRIDGEWATER, N.J., June 14, 2018-- Foamix Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams ...

  • Why Galmed Pharmaceuticals Stock Rose 151% on June 12
    Market Realistlast month

    Why Galmed Pharmaceuticals Stock Rose 151% on June 12

    Galmed Pharmaceuticals (GLMD) stock rose 151.3% on June 12. Galmed stock rose after the company announced top-line results from the global 52-week phase 2b ARREST trial. The company is conducting the phase 2b ARREST trial to evaluate the safety and efficacy of its Aramchol for the treatment of individuals with non-alcoholic steatohepatitis (or NASH).

  • May Best Growth Stocks
    Simply Wall St.2 months ago

    May Best Growth Stocks

    Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FOMX earnings conference call or presentation 9-May-18 12:30pm GMT

    Q1 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • With A -124.01% Earnings Drop, Did Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Really Underperform?
    Simply Wall St.2 months ago

    With A -124.01% Earnings Drop, Did Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Really Underperform?

    For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...

  • Associated Press2 months ago

    Foamix: 1Q Earnings Snapshot

    On a per-share basis, the Rehovot, Israel-based company said it had a loss of 69 cents. The acne treatment developer posted revenue of $906,000 in the period. Foamix shares have decreased 15 percent since ...

  • GlobeNewswire2 months ago

    Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update

    REHOVOT, Israel, May 08, 2018-- Foamix Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs ...

  • GlobeNewswire2 months ago

    Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that the final patient has been enrolled and dosed in its third Phase 3 study, FX2017-22, evaluating the efficacy and safety of its topical minocycline foam 4%, or FMX101. FX2017-22 is a double-blind, vehicle-controlled, multi-center study conducted in the United States that has been enrolling patients with moderate-to-severe acne.  Patients were randomized 1:1 to either FMX101 or vehicle, with once daily treatment for 12 weeks. The primary endpoints are 1) the proportion of patients achieving success at week 12 based on an Investigator’s Global Assessment (with success defined as a score of “clear” or “almost clear” and at least a 2 category improvement from baseline), and 2) the mean change from baseline in inflammatory lesion counts in each treatment group at week 12.  Safety evaluation includes reported adverse events, assessments of tolerability, clinical laboratory tests and vital signs.

  • Cheniere Energy Partners Holdings And Other Great Growth Stocks
    Simply Wall St.4 months ago

    Cheniere Energy Partners Holdings And Other Great Growth Stocks

    Looking to add potential meaningful upside to your portfolio, but unsure where to start? Stocks such as Cheniere Energy Partners Holdings and Foamix Pharmaceuticals are considered to be high growthRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of FOMX earnings conference call or presentation 28-Feb-18 1:30pm GMT

    Q4 2017 Foamix Pharmaceuticals Ltd Earnings Call

  • ACCESSWIRE5 months ago

    Foamix Pharmaceuticals Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018, at 8:30 ...

  • When Will Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Become Profitable?
    Simply Wall St.5 months ago

    When Will Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Become Profitable?

    Foamix Pharmaceuticals Ltd’s (NASDAQ:FOMX): Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skinRead More...

  • Allergan/Paratek's Acne Candidate NDA Filing Accepted by FDA
    Zacks7 months ago

    Allergan/Paratek's Acne Candidate NDA Filing Accepted by FDA

    Allergan (AGN) and partner Paratek announces that its new drug application for Seysara has been accepted for review by the FDA for moderate to severe acne vulgaris.

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of FOMX earnings conference call or presentation 15-Nov-17 1:30pm GMT

    Q3 2017 Foamix Pharmaceuticals Ltd Earnings Call

  • Associated Press8 months ago

    Foamix reports 3Q loss

    On a per-share basis, the Rehovot, Israel-based company said it had a loss of 47 cents. The acne treatment developer posted revenue of $901,000 in the period. Foamix shares have declined 51 percent since ...